3 business development jobs found in Stamford, CT

Pharmaceutical Sales Representative - Primary Care (Entry Level or Specialty) Pharmaceutical Sales Rep - Job Description   We are a healthcare industry specialty distributor serving the healthcare and medical supply markets. We are driven to meet the needs of healthcare professionals in several therapeutic areas.  Our healthcare professional and physician customers benefit from a diverse group of products and services. Who are we looking for in our Pharmaceutical Sales Rep professionals? We are looking for healthcare and business-minded professionals, with successful sales track records who strive for organizational success, and seek career growth. What can you expect from a career with us as a Pharmaceutical Sales Representative? As a Pharmaceutical Sales Representative, you are responsible for driving profitable sales growth by developing, maintaining, and advancing accounts by regularly contacting medical offices,...

Purdue Pharma L.P. and its subsidiaries develop, manufacture and market medications to meet the evolving needs of healthcare professionals, patients, and caregivers. We were founded by physicians, and we are currently led by a physician. Beyond our efforts to provide quality medications, Purdue is committed to supporting national, regional and local collaborations to drive innovations in patient care.

Amarin Corporation plc (“Amarin”) is a rapidly growing pharmaceutical company developing and selling therapeutics to improve cardiovascular health. Amarin, a publicly traded company (NASDAQ: AMRN) with approximately 900 employees, is headquartered in Dublin, Ireland and has its US operations (Amarin Pharma Inc.) based in Central New Jersey. Amarin has successfully developed, registered and launched VASCEPA® in the U.S. market with a network of third-party companies aligned with Amarin to advance commercialization of VASCEPA® globally. In the U.S., VASCEPA® was launched in 2013 for its initial indication of as a treatment of Very High Triglycerides (i.e. patients with TG levels ≥ 500mg/dL). In November 2018, unprecedented clinical results were announced from a landmark global cardiovascular outcomes study in which VASCEPA®demonstrated a significantly lower risk of cardiovascular events beyond the current standard of care for cholesterol management....